Phase I/II, Open Label, Dose Escalating Study To Investigate Safety, Tolerability, And Preliminary Efficacy Of The Trifunctional Anti-HER-2/neu x Anti-CD3 Antibody Ertumaxomab In Patients With HER-2/neu Expressing (1+/SISH positive, 2+ and 3+) Solid Tumors Progressing After Standard Therapy.

Trial Profile

Phase I/II, Open Label, Dose Escalating Study To Investigate Safety, Tolerability, And Preliminary Efficacy Of The Trifunctional Anti-HER-2/neu x Anti-CD3 Antibody Ertumaxomab In Patients With HER-2/neu Expressing (1+/SISH positive, 2+ and 3+) Solid Tumors Progressing After Standard Therapy.

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 26 May 2016

At a glance

  • Drugs Ertumaxomab (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; Pharmacogenomic
  • Acronyms ERTUSO
  • Most Recent Events

    • 04 May 2016 Status changed from active, no longer recruiting to discontinued.
    • 03 Jun 2014 interim results in 11 patients presented at the 50th Annual Meeting of the American Society of Clinical Oncology.
    • 30 Mar 2012 Additional lead trial investigator (Salah-Eddin Al-Batran) identified as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top